Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 556 to 570 of 1505 results for patients and public

  1. Blarcamesine for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [TSID12157]

    Awaiting development Reference number: GID-TA11717 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Budesonide (Jorveza) for maintaining remission of eosinophilic oesophagitis in people 2 years and over [ID6486]

    Awaiting development Reference number: GID-TA11623 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive high-risk early breast cancer [ID6620]

    Awaiting development Reference number: GID-TA11403 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Oveporexton for treating type 1 narcolepsy [ID6622]

    Awaiting development Reference number: GID-TA11820 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Zimislecel for treating type 1 diabetes in people 12 years and over with impaired hypoglycaemic awareness and severe hypoglycaemia [ID6624]

    Awaiting development Reference number: GID-TA11816 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Talquetamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more lines of treatment including a proteasome inhibitor and lenalidomide [ID6625]

    Awaiting development Reference number: GID-TA11815 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy [ID6515]

    Awaiting development Reference number: GID-TA11654 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Datopotamab deruxtecan with durvalumab and carboplatin for untreated TROP2-positive advanced non-small-cell lung cancer without actionable genomic alterations [ID6522]

    Awaiting development Reference number: GID-TA11671 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Denosumab biosimilar for Giant cell-rich tumours of bone or Skeletal events in bone malignancies ID12150

    Awaiting development Reference number: GID-TA11783 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Carfilzomib in combination for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID12176]

    Awaiting development Reference number: GID-TA11752 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Inebilizumab for treating immunoglobulin G4-related disease [TSID12107]

    Awaiting development Reference number: GID-TA11665 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Ixekizumab for treating enthesitis-related arthritis and juvenile psoriatic arthritis in people 2 to 17 years [ID6590]

    Awaiting development Reference number: GID-TA11792 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Atrasentan for treating primary IgA nephropathy [ID6558]

    Awaiting development Reference number: GID-TA11756 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Fidrisertib for reducing heterotopic ossification caused by fibrodysplasia ossificans progressiva in people 5 years and over [TSID12216]

    Awaiting development Reference number: GID-TA11805 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Tildrakizumab for treating active psoriatic arthritis [TSID12218]

    Awaiting development Reference number: GID-TA11807 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development